首页> 美国卫生研究院文献>European Journal of Case Reports in Internal Medicine >The Use of Thalidomide in Severe Refractory Anaemia Due to Gastric Antral Vascular Ectasia (GAVE) in Cirrhosis?
【2h】

The Use of Thalidomide in Severe Refractory Anaemia Due to Gastric Antral Vascular Ectasia (GAVE) in Cirrhosis?

机译:由于胃窦血管异血(饲养)在肝脏血管异血(饲养)中使用沙利度胺在严重的难治性贫血中使用?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Gastric antral vascular ectasia (GAVE) is a rare cause of upper gastrointestinal bleeding associated with cirrhosis. The first-line treatment is endoscopic therapy with argon plasma coagulation (APC). There is a high recurrence rate, but some evidence suggests that thalidomide could play an important role in controlling refractory anaemia due to GAVE. The authors present the case of a cirrhotic patient with a recent diagnosis of GAVE, who underwent multiple endoscopic treatments and blood transfusions because of haematemesis. The patient started thalidomide and 6 months later, there was no recurrence of haematemesis and haemoglobin levels were stable, with no reported adverse effects.
机译:胃窦血管异血(发出)是与肝硬化相关的上胃肠道出血的罕见原因。第一线治疗是具有氩等离子体凝血(APC)的内窥镜治疗。递归率高,但有些证据表明沙利度胺可能在控制由于给予的难治性贫血中起重要作用。作者呈现了肝硬化患者的肝硬化患者,近期诊断,因血液缺血而接受多种内窥镜治疗和血液输血。患者开始了沙利度胺和6个月后,血红蛋白和血红蛋白水平没有复发,没有报告的不良反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号